Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ironwood Pharmaceuticals (IRWD) EBT: 2010-2025

Historic EBT for Ironwood Pharmaceuticals (IRWD) over the last 16 years, with Sep 2025 value amounting to $68.0 million.

  • Ironwood Pharmaceuticals' EBT rose 291.62% to $68.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $195.5 million, marking a year-over-year increase of 226.13%. This contributed to the annual value of $167.1 million for FY2024, which is 114.23% up from last year.
  • Latest data reveals that Ironwood Pharmaceuticals reported EBT of $68.0 million as of Q3 2025, which was up 79.84% from $37.8 million recorded in Q2 2025.
  • In the past 5 years, Ironwood Pharmaceuticals' EBT registered a high of $125.9 million during Q4 2024, and its lowest value of -$1.1 billion during Q2 2023.
  • For the 3-year period, Ironwood Pharmaceuticals' EBT averaged around -$85.3 million, with its median value being $18.9 million (2024).
  • Its EBT has fluctuated over the past 5 years, first spiked by 1,106.52% in 2021, then slumped by 2,100.97% in 2023.
  • Over the past 5 years, Ironwood Pharmaceuticals' EBT (Quarterly) stood at $46.3 million in 2021, then skyrocketed by 56.23% to $72.3 million in 2022, then crashed by 371.46% to -$196.2 million in 2023, then soared by 164.17% to $125.9 million in 2024, then soared by 291.62% to $68.0 million in 2025.
  • Its last three reported values are $68.0 million in Q3 2025, $37.8 million for Q2 2025, and -$36.3 million during Q1 2025.